1.87
price up icon0.54%   0.01
 
loading
Cellectis Adr stock is traded at $1.87, with a volume of 29,798. It is up +0.54% in the last 24 hours and up +3.89% over the past month. Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
See More
Previous Close:
$1.86
Open:
$1.86
24h Volume:
29,798
Relative Volume:
0.61
Market Cap:
$187.18M
Revenue:
$5.15M
Net Income/Loss:
$-65.35M
P/E Ratio:
-0.9397
EPS:
-1.99
Net Cash Flow:
$-20.85M
1W Performance:
+0.00%
1M Performance:
+3.89%
6M Performance:
-35.96%
1Y Performance:
-33.69%
1-Day Range:
Value
$1.85
$1.89
1-Week Range:
Value
$1.8187
$1.98
52-Week Range:
Value
$1.70
$3.7735

Cellectis Adr Stock (CLLS) Company Profile

Name
Name
Cellectis Adr
Name
Phone
-
Name
Address
-
Name
Employee
216
Name
Twitter
@cellectis
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
CLLS's Discussions on Twitter

Compare CLLS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
CLLS 1.87 187.18M 5.15M -65.35M -20.85M -1.99
VRTX 450.97 116.38B 10.63B -479.80M -1.35B 13.33
REGN 738.00 82.09B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.14B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.25B 3.30B -501.07M 1.03B 11.54

Cellectis Adr Stock (CLLS) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-17-23 Initiated Bryan Garnier Buy
May-18-22 Upgrade Robert W. Baird Neutral → Outperform
Jan-06-22 Downgrade Wells Fargo Overweight → Equal Weight
Nov-30-21 Initiated JMP Securities Mkt Outperform
Nov-08-21 Downgrade William Blair Outperform → Mkt Perform
Oct-08-21 Downgrade Robert W. Baird Outperform → Neutral
Apr-28-21 Downgrade Guggenheim Buy → Neutral
Mar-16-21 Upgrade Robert W. Baird Neutral → Outperform
Aug-19-20 Upgrade Citigroup Neutral → Buy
May-12-20 Initiated Robert W. Baird Outperform
Mar-06-20 Downgrade Goldman Neutral → Sell
Oct-30-19 Resumed Guggenheim Buy
Aug-09-19 Initiated BTIG Research Buy
May-24-19 Resumed Citigroup Neutral
Mar-14-19 Initiated William Blair Outperform
Dec-19-18 Initiated Goldman Neutral
Jul-16-18 Initiated Barclays Overweight
Mar-16-18 Initiated Guggenheim Neutral
Sep-05-17 Downgrade SunTrust Buy → Hold
Sep-05-17 Reiterated Wells Fargo Outperform
Mar-02-17 Initiated Instinet Buy
Feb-28-17 Initiated Wells Fargo Outperform
Apr-05-16 Initiated Ladenburg Thalmann Buy
Mar-02-16 Initiated Sun Trust Rbsn Humphrey Buy
Jul-20-15 Initiated BofA/Merrill Buy
Apr-20-15 Initiated Jefferies Buy
Apr-20-15 Initiated Piper Jaffray Overweight
View All

Cellectis Adr Stock (CLLS) Latest News

pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Fall Sharply in Tuesday Trading - MSN

Nov 20, 2024
pulisher
Nov 12, 2024

Cellectis's SWOT analysis: gene-editing firm's stock faces pivotal year ahead - Investing.com

Nov 12, 2024
pulisher
Nov 06, 2024

Cellectis stock touches 52-week low at $1.75 amid market challenges - Investing.com

Nov 06, 2024
pulisher
Nov 06, 2024

Earnings call: Cellectis reports robust cash reserves, new R&D initiatives - Investing.com

Nov 06, 2024
pulisher
Nov 05, 2024

Baird maintains $10 target on Cellectis amid strong AZN partnership - Investing.com

Nov 05, 2024
pulisher
Nov 04, 2024

Cellectis earnings missed by $0.03, revenue topped estimates By Investing.com - Investing.com South Africa

Nov 04, 2024
pulisher
Nov 04, 2024

Cellectis earnings missed by $0.03, revenue topped estimates - Investing.com

Nov 04, 2024
pulisher
Oct 30, 2024

Cellectis stock touches 52-week low at $1.77 amid market shifts By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 30, 2024

500: Something went wrong - Investing.com

Oct 30, 2024
pulisher
Oct 25, 2024

European Equities Traded in the US as American Depositary Receipts Nudge Lower in Tuesday Trading - MSN

Oct 25, 2024
pulisher
Oct 12, 2024

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remains Down for Week - MSN

Oct 12, 2024
pulisher
Oct 09, 2024

European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN

Oct 09, 2024
pulisher
Oct 09, 2024

European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN

Oct 09, 2024
pulisher
Oct 03, 2024

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN

Oct 03, 2024
pulisher
Oct 02, 2024

Monthly information on share capital and company voting rights - GlobeNewswire Inc.

Oct 02, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Cellectis stock rides wave of innovation amid biotech challenges - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Cellectis stock rides wave of innovation amid biotech challenges By Investing.com - Investing.com South Africa

Sep 27, 2024
pulisher
Sep 13, 2024

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN

Sep 13, 2024
pulisher
Sep 06, 2024

European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN

Sep 06, 2024
pulisher
Aug 30, 2024

European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN

Aug 30, 2024
pulisher
Aug 22, 2024

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN

Aug 22, 2024
pulisher
Aug 21, 2024

European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN

Aug 21, 2024
pulisher
Jul 26, 2024

A year in review: Cellectis ADR (CLLS)’s performance in the last year - US Post News

Jul 26, 2024
pulisher
Jul 05, 2024

Monthly information on share capital and company voting rights - GlobeNewswire Inc.

Jul 05, 2024
pulisher
Jun 19, 2024

Market Insights: Cellectis ADR (CLLS)'s Notable Drop of -5.84, Closing at 2.02 – DWinneX - The Dwinnex

Jun 19, 2024
pulisher
Jun 18, 2024

Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors - The Globe and Mail

Jun 18, 2024
pulisher
Jun 18, 2024

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results - The Globe and Mail

Jun 18, 2024
pulisher
Jun 14, 2024

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading - MSN

Jun 14, 2024
pulisher
Jun 12, 2024

Cellectis shares target cut by Oppenheimer on revised model post-Q1 results - Investing.com India

Jun 12, 2024
pulisher
Jun 12, 2024

Cellectis shares target cut by Oppenheimer on revised model post-Q1 results By Investing.com - Investing.com UK

Jun 12, 2024
pulisher
May 31, 2024

European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower - MSN

May 31, 2024
pulisher
May 31, 2024

Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By Investing.com - Investing.com India

May 31, 2024
pulisher
May 30, 2024

Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca - Investing.com India

May 30, 2024
pulisher
May 17, 2024

European Equities Traded in the US as American Depositary Receipts Fall Again in Tuesday Trading - MSN

May 17, 2024
pulisher
Dec 16, 2023

CellectisADR (CLLS) Price Target Increased by 20.85% to 11.75 - MSN

Dec 16, 2023
pulisher
Nov 01, 2023

AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions - AstraZeneca

Nov 01, 2023
pulisher
Feb 21, 2023

There's a Lot of Upside For Emerging Gene-Editing Companies - The Globe and Mail

Feb 21, 2023
pulisher
Jun 30, 2022

Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing - Nature.com

Jun 30, 2022
pulisher
Apr 28, 2022

Cytovia Therapeutics To Go Public Via $600 Million SPAC Merger - Equities News

Apr 28, 2022
pulisher
Apr 09, 2021

Cellectis Completes Sale of $47 million through its ATM program - The Globe and Mail

Apr 09, 2021
pulisher
Mar 29, 2021

Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq - The Globe and Mail

Mar 29, 2021
pulisher
Feb 21, 2021

Current Cathie Wood Portfolio 2021: Ark Invest Holdings - New Trader U

Feb 21, 2021
pulisher
Nov 21, 2019

The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon - Yahoo Finance

Nov 21, 2019
pulisher
Jan 17, 2018

30 Stocks Moving In Wednesday's Pre-Market SessionAdtran Holdings (NASDAQ:ADTN), Adient (NYSE:ADNT) - Benzinga

Jan 17, 2018
pulisher
Oct 18, 2017

7 Gene Editing Companies Investors Should Watch - Nanalyze

Oct 18, 2017
pulisher
Sep 05, 2017

25 Stocks Moving In Tuesday's Pre-Market SessionBioCryst Pharma (NASDAQ:BCRX) - Benzinga

Sep 05, 2017
pulisher
Aug 28, 2017

25 Stocks Moving In Monday's Pre-Market SessionAltisource Portfolio (NASDAQ:ASPS) - Benzinga

Aug 28, 2017
pulisher
Feb 08, 2017

Top 10 Luxury Car Brands In The World - Insider Monkey

Feb 08, 2017
pulisher
Aug 11, 2016

Cellectis (CLLS) Stock Price, News & AnalysisNASDAQ - MarketBeat

Aug 11, 2016
pulisher
Oct 29, 2015

Morning Market GainersCellectis (NASDAQ:CLLS) - Benzinga

Oct 29, 2015
pulisher
Oct 27, 2015

New Strong Buy Stocks for October 27th - Nasdaq

Oct 27, 2015

Cellectis Adr Stock (CLLS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
Cap:     |  Volume (24h):